Judge OKs Mylan's Acne Generic But Keeps Patent Intact

Law360, New York (April 30, 2012, 5:40 PM EDT) -- A New Jersey federal judge on Monday held that two generic anti-acne drugs made by Mylan Pharmaceuticals Inc. and Impax Laboratories Inc. do not infringe a patent for Warner Chilcott Co. LLC’s brand-name drug Doryx, but refused to find a Doryx patent invalid.

Doryx is manufactured by Mayne Pharma Group but is marketed by Warner Chilcott, the suit says.

U.S. District Judge William J. Martini ruled that Warner Chilcott didn’t prove that Mylan’s and Impax’s pills contain a stabilizing coat, as specified by Mayne’s patent....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.